This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Gneiss, C Articles by Deisenhammer, F Search for Related Content PubMed PubMed Citation Articles by Gneiss, C Articles by Deisenhammer, F Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Multiple Sclerosis Social Bookmarking                         What's this?

Interferon-beta: the neutralizing antibody (NAb) titre predicts reversion to NAb negativity

Department of Neurology, University of Innsbruck, Anichstrasse 35, 6020 Innsbruck, Austria

M Reindl

Department of Neurology, University of Innsbruck, Anichstrasse 35, 6020 Innsbruck, Austria

A Lutterotti

Department of Neurology, University of Innsbruck, Anichstrasse 35, 6020 Innsbruck, Austria

R Ehling

Department of Neurology, University of Innsbruck, Anichstrasse 35, 6020 Innsbruck, Austria

R Egg

Department of Neurology, University of Innsbruck, Anichstrasse 35, 6020 Innsbruck, Austria

M Khalil

Department of Neurology, University of Innsbruck, Anichstrasse 35, 6020 Innsbruck, Austria

T Berger

Department of Neurology, University of Innsbruck, Anichstrasse 35, 6020 Innsbruck, Austria

F Deisenhammer

Department of Neurology, University of Innsbruck, Anichstrasse 35, 6020 Innsbruck, Austria, florian.deisenhammer{at}uibk.ac.at

Background: It has been reported that in some patients with MS who develop neutralizing antibodies (NAbs) against interferon beta (IFNb), antibody levels can initially increase and then decrease thereafter even when treatment is continued. Objective: To determine whether NAb titre correlates with time to reversion to NAb negativity in patients with multiple sclerosis (MS). Methods: Twenty-eight patients with MS who were NAb-positive during treatment with one of the currently available IFNbs were included in this retrospective study. NAb titres were determined by the myxovirus resistance protein A induction assay. Patients were considered NAb-positive if they had at least two consecutive samples with titres of]/20 neutralizing units (NU). Reversion to NAb-negative status was defined as two consecutive negative samples (NAb titre of B/20 NU) after NAb positivity. Results: When measured two years after treatment initiation, a NAb titre of B/75 NU had a 91.7% sensitivity and a 87.5% specificity for reversion to NAb negativity in the following two years (after a total of four years of treatment). In addition, somewhat surprisingly, patients whose serum converted to NAb-negative generally developed peak NAb titres earlier than patients who remained NAb-positive (mean time of first detection was 21 versus 38 months, respectively). Conclusion: The NAb titre might support treatment decisions in patients with MS whose test results are positive for NAbs.

Key Words: interferon beta • multiple sclerosis • neutralizing antibodies

Multiple Sclerosis, Vol. 10, No. 5, 507-510 (2004)
DOI: 10.1191/1352458504ms1074oa


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				C. Gneiss, P.-M. Koudouovoh-Tripp, S. Ropele, T. Gotwald, R. Ehling, A. Lutterotti, F. Aichner, G. Ladurner, C. Eggers, F. Schautzer, et al. Influence of interferon-beta therapy switching on neutralizing antibody titres: results from the Austrian Switch Study Multiple Sclerosis, December 1, 2009; 15(12): 1481 - 1488. [Abstract] [PDF]

				A Millonig, D Rudzki, M Holzl, R Ehling, C Gneiss, B Kunz, T Berger, M Reindl, and F Deisenhammer High-dose intravenous interferon beta in patients with neutralizing antibodies (HINABS): a pilot study Multiple Sclerosis, August 1, 2009; 15(8): 977 - 983. [Abstract] [PDF]

				M Ravnborg, K Bendtzen, O Christensen, P. Jensen, D Hesse, M. Tovey, and P. Sorensen Treatment with azathioprine and cyclic methylprednisolone has little or no effect on bioactivity in anti-interferon beta antibody-positive patients with multiple sclerosis Multiple Sclerosis, March 1, 2009; 15(3): 323 - 328. [Abstract] [PDF]

				G Giovannoni, O Barbarash, F Casset-Semanaz, J King, L Metz, G Pardo, J Simsarian, P. Sorensen, B Stubinski, and on behalf of the Rebif(R) New Formulation Study Gr Safety and immunogenicity of a new formulation of interferon {beta}-1a (Rebif(R) New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results Multiple Sclerosis, February 1, 2009; 15(2): 219 - 228. [Abstract] [PDF]

				P. Soelberg Sorensen Review: Neutralizing antibodies against interferon-beta Therapeutic Advances in Neurological Disorders, September 1, 2008; 1(2): 125 - 141. [Abstract] [PDF]

				P. Sorensen, N Koch-Henriksen, E. Flachs, and K Bendtzen Is the treatment effect of IFN-{beta} restored after the disappearance of neutralizing antibodies? Multiple Sclerosis, July 1, 2008; 14(6): 837 - 842. [Abstract] [PDF]

				R. A Farrell and G. Giovannoni Measuring and management of Anti-Interferon Beta Antibodies in subjects with Multiple Sclerosis Multiple Sclerosis, June 1, 2007; 13(5): 567 - 577. [Abstract] [PDF]

				A. AL-Sabbagh Neutralizing antibodies in MS therapy: reviewing the Rebif experience Multiple Sclerosis, May 1, 2007; 13(1_suppl): 8 - 13. [Abstract] [PDF]

				F. Deisenhammer Neutralizing antibody (NAb) assays in multiple sclerosis patients receiving interferon-{beta} therapy Multiple Sclerosis, May 1, 2007; 13(1_suppl): 44 - 48. [Abstract] [PDF]

				C Gneiss, P Tripp, F Reichartseder, R Egg, R Ehling, A Lutterotti, M Khalil, B Kuenz, I Mayringer, M Reindl, et al. Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients Multiple Sclerosis, November 1, 2006; 12(6): 731 - 737. [Abstract] [PDF]